Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Staber, PB; Brezinschek, R; Linkesch, W; Sill, H; Neumeister, P.
Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.
Haematologica. 2003; 88(8):ECR29-ECR29
(- Case Report)
[OPEN ACCESS]
PubMed
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Staber Philipp
- Co-Autor*innen der Med Uni Graz
- Linkesch Werner
- Neumeister Peter
- Sill Heinz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- We report a chronic myeloid leukemia (CML) patient in chronic phase (CP) who developed blast crisis (BC) under imatinib mesylate administered in a dose reduced and non-continuous fashion because of hematologic intolerance. The patient underwent nonmyeloablative stem-cell transplant from a matched unrelated donor, but failed to achieve full donor chimerism and antileukemic response resulting in persistence of advanced disease. Complete hematologic, cytogenetic and molecular responses were attained 5 weeks after readministration of regularly dosed imatinib and two-step nested RT-PCR confirmed molecular remission throughout a 6 month follow-up period. This is the first case demonstrating that imatinib mesylate is a highly effective and safe treatment option to induce durable molecular remission in patients with CML who remain in myeloid blast crisis after nonmyeloablative allogeneic stem-cell transplantation.
- Find related publications in this database (using NLM MeSH Indexing)
- Antineoplastic Agents - therapeutic use
- Blast Crisis - drug therapy Blast Crisis - therapy
- Female -
- Hematopoietic Stem Cell Transplantation - methods
- Hematopoietic Stem Cells - drug effects
- Humans -
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy
- Middle Aged -
- Myeloablative Agonists - therapeutic use
- Piperazines - therapeutic use
- Pyrimidines - therapeutic use
- Transplantation, Homologous -